|
|
Article: U.S. BioDefense Forms Stem Cell Subsidiary, Prepares IPO.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
In an attempt to position its stem cell division for an initial public offering, U.S. BioDefense Inc. has formed a new subsidiary that will boost transplantation research in areas such as liver failure and brain and spinal cord injury.
The plan first is to form Stem Cell Research Institute of California Inc., and then to file for an IPO, possibly later this year, but the company has not disclosed a timeline.
Proceeds from that IPO then would be used to establish the first - with more to follow - Stem Cell Center of Excellence in Southern California. The center would focus on in-licensed research of the liver cell progenitor and its ...